Last week marked International Women’s Day (March 8), and while we recognize the remarkable women in science and healthcare at the Research Institute every day of the year, it seems especially fitting that this news roundup features some of those role models as they receive accolades and awards. Hematology researcher, Lindsey George, MD, was honored for her breakthrough work in developing a gene therapy for hemophilia B, while our CEO and President, Madeline Bell, ranked on the Top 25 Women Leaders list by Modern Healthcare. Meanwhile, in other news, researchers published findings on obesity and vitamin D, the use of machine learning for early sepsis detection, and a promising drug to treat some mitochondrial disorders.
Tag Archive: Lindsey George
Editor’s Note: Jacqueline Hunter, PhD, a postdoctoral fellow in the Wolfe Laboratory, wrote this article as part of the Advanced Career Exploration (ACE) Fellowship at Children’s Hospital of Philadelphia Research Institute. The ACE program gives fellows the opportunity to pursue projects beyond their main research focus. We’re especially excited to share Dr. Hunter’s work during National Postdoc Appreciation Week.
Normally, the body responds to a bleeding event by forming a clot, which is a complicated process involving multiple proteins in an elegantly orchestrated cascade. When specific proteins of this cascade are absent, one of several debilitating disorders can occur that result in recurrent spontaneous bleeding into the joints and muscles. Researchers at Children’s Hospital of Philadelphia are using clever maneuvering to figure out new therapeutic options for patients with hemophilia A and B.
Microbes, monitors, and miraculous medicine converge in this week’s roundup of research-related headlines at Children’s Hospital of Philadelphia. Keep reading to learn more about new concerns for commercially available baby monitors reported by our researchers, one family’s inspirational story of resilience and recovery after their baby daughter battled a brain tumor, and exciting upcoming events in the CHOP community, including the fifth annual symposium for microbiome research.
Hematologists have grappled for many years to understand the basic mechanisms underlying why some young patients with the inherited bleeding disorder hemophilia A develop inhibitory antibodies, also known as factor VIII (FVIII) inhibitors, to protein replacement therapy. The presence of FVIII inhibitors is a serious obstacle that makes it difficult and extremely expensive to treat their hemophilia, leads to complications such as joint disease, and increases mortality.
Such a major challenge requires major brain power. So the National Institutes of Health called on the scientific community to reframe the question: Why is FVIII so immunogenic?
By definition, entrepreneurs are energetic leaders who challenge existing ideas to drive impactful change. Entrepreneurs think outside the box, follow their passion, and stay resilient and resourceful to achieve their goals. At Children’s Hospital of Philadelphia, fellows in the Entrepreneurial Science Scholars Program do all of these things — and more — to improve the health of children and families.
On Feb. 22, we celebrated this year’s CHOP Entrepreneurial Science Scholars, a group of six clinician-researchers who are conducting pioneering research and innovation in diverse and critical fields. The CHOP Entrepreneurial Science Scholars Program aims to produce highly trained investigators skilled in translational research and the generation of creative solutions to biomedical problems. Joseph St. Geme, MD, Physician-in-Chief and Chairman of the Department of Pediatrics at CHOP, hosted the event.
Your holiday season has been hectic, no doubt. Catch up with an early gift from us: Our biweekly roundup of research news from Children’s Hospital of Philadelphia comes with all the trimmings!